Entrada Therapeutics, Inc.
Entrada Therapeutics, Inc. (TRDA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 trdaq22026earningsrelease.htm EX-99.1 Document Entrada Therapeutics Reports Second Quarter 2026 Financial Results -- Company to report ELEVATE-44-201 data from Cohort 1 open-label period by year-end 2026 -- -- ELEVATE-44-201 Cohort 2 enrollment complete with data expect
5AM Ventures V, L.P. sold 116,474 shares of Entrada Therapeutics, Inc. (TRDA) at an average of $6.93 ($6.85–$6.93, $0.81M total) across 2 trades over 2026-07-30 to 2026-07-31.
PARMAR KUSH sold 116,474 indirectly-held shares of Entrada Therapeutics, Inc. (TRDA) at an average of $6.93 ($6.85–$6.93, $0.81M total) across 2 trades over 2026-07-30 to 2026-07-31.
Over the past 7 days, alphai's AI scored 1 news story mentioning TRDA (Entrada Therapeutics, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent TRDA coverage spans financial news, insider activity and earnings.
In the last 30 days, TRDA insiders filed 4 SEC Form 4 transactions — no purchases and 4 sales ($1.6M). The most active reporter was 5AM Ventures V, L.P. with 2 filings.
Near-term catalysts are pushed into a defined calendar (Oct 2026, H1 2027, year-end 2026), while cash runway extends into Q3 2027.
This is a routine insider sale by a large 10% owner, with no 10b5-1 plan cited, but it does not disclose new fundamentals.
The filing is a routine insider sale with no stated 10b5-1 plan, but it does not provide new fundamentals or guidance.
The approved plan/ESPP amendments can increase future share issuance capacity, which may be viewed as modestly dilutive but also supports ongoing equity compensation/employee retention.
Litigation risk is elevated and may reinforce bearish positioning after the stock’s sharp drop on May 7.
alphai scores every news story that mentions TRDA with an AI model for sentiment and relevance, and aggregates insider trades from Entrada Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Entrada Therapeutics, Inc. (TRDA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 trdaq22026earningsrelease.htm EX-99.1 Document Entrada Therapeutics Reports Second Quarter 2026 Financial Results -- Company to report ELEVATE-44-201 data from Cohort 1 open-label period by year-end 2026 -- -- ELEVATE-44-201 Cohort 2 enrollment complete with data expect
4 min read5AM Ventures V, L.P. sold 116,474 shares of Entrada Therapeutics, Inc. (TRDA) at an average of $6.93 ($6.85–$6.93, $0.81M total) across 2 trades over 2026-07-30 to 2026-07-31.
1 min readPARMAR KUSH sold 116,474 indirectly-held shares of Entrada Therapeutics, Inc. (TRDA) at an average of $6.93 ($6.85–$6.93, $0.81M total) across 2 trades over 2026-07-30 to 2026-07-31.
1 min readEntrada Therapeutics, Inc. (TRDA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001689375 0001689375 2026-06-10 2026-06-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor
3 min readPomerantz LLP said it is investigating potential securities fraud or unlawful practices involving Entrada Therapeutics (NASDAQ: TRDA) and certain officers/directors, on behalf of investors. The probe follows Entrada’s May 7, 2026 press release on Phase 1/2 ELEVATE-44-201 Cohort 1 topline data, which showed a 2.36% dystrophin production increase. On that day, TRDA shares fell $9.18 (57.27%) to $6.85.
3 min readHolzer & Holzer, LLC has initiated an investigation into Entrada Therapeutics, Inc. (TRDA) to determine if the company violated federal securities laws. This investigation follows a drop in Entrada's stock price after the announcement of Duchenne muscular dystrophy study results, which showed dystrophin increase below analyst expectations. Shareholders who suffered losses are encouraged to contact the law firm to discuss their legal rights.
3 min readSethuraman Natarajan, President of Research & Development at Entrada Therapeutics, Inc. (NASDAQ:TRDA), sold 25,907 shares worth approximately $398,809 on May 4, 2026. This sale was made under a Rule 10b5-1 trading plan adopted in November 2024. InvestingPro analysis suggests the stock is overvalued, and the company, valued at $530 million, is quickly burning through cash despite holding more cash than debt.
4 min readThis article provides an AI-driven analysis of Entrada Therapeutics Inc. (NASDAQ: TRDA), indicating positive near-term sentiment within a long-term strength context, despite a weak mid-term bias. It outlines distinct trading strategies including position, momentum breakout, and risk hedging, accompanied by multi-timeframe signal analysis and specific entry/exit points with risk-reward ratios.
5 min readRoyce & Associates LP increased its stake in Entrada Therapeutics, Inc. (NASDAQ:TRDA) by 54.8% in Q3, now owning 345,507 shares valued at $2,004,000. Other institutional investors have also adjusted their holdings, with institutional ownership now at 86.39%. Despite some negative sentiment regarding earnings forecasts, analysts have a "Moderate Buy" rating for Entrada Therapeutics with a consensus target price of $18.50.
2 min readBOSTON, Oct. 28, 2025 ( GLOBE NEWSWIRE ) -- Entrada Therapeutics, Inc. ( NASDAQ:TRDA ) today announced the Company will participate in two upcoming investor conferences.
3 min read
